Список проголосовавших за комментарий " On The Wires<ul><li>Turkcell (<strong>TKC</strong>) provided an update regarding the Board of Directors resolution on buy-back of securities. For reference, the Board of Directors authorized the management to execute share buy-back transactions on July 27, 2016, within the scope of the announcements dated July 21, 2016 and July 25, 2016 made by the Capital Markets Board. In this context, it was resolved that the maximum fund amount set aside for share buy-back would be TRY150 million and the maximum share number to be bought back would be determined so as not to exceed this amount. The Board of Directors has decided to increase the previously mentioned fund amount to TRY300 million in order to be utilized for share buy-back, including its American Depositary Receipts being traded at the New York Stock Exchange (NYSE) and bond buy-back; and to buy, sell and/or redeem at the price and level that the management will determine, within the maximum fund amount set above.</li><li>Trillium Therapeutics Inc. (<strong>TRIL</strong>) announced that it has initiated dosing in its second Phase 1 clinical trial with TTI-621 (SIRPaFc) in patients with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides. Trillium is developing TTI-621 as a novel checkpoint inhibitor of the innate immune system, and the drug is currently being evaluated in an ongoing 10-cohort Phase 1b study in patients with relapsed or refractory hematologic malignancies. </li></ul>"